The
panini is on Pfizer’s side. Pfizer made
US-$14.6 billion in revenue in the first quarter of 2021, up US-$4 billion from this time in 2020.
- The pharma giant said its COVID-19 vaccine that it developed with BioNTech generated US-$3.5 billion in revenues, about a quarter of all sales.
Pandemic Profits: Pfizer predicts US-$26 billion in COVID-19 vax sales this year, nearly double their previous expectation of US-$15 billion.
- The company wants to turn its COVID-19 vaccine into a long-term business by developing new formulas that are easier to store and ones that can fend off variants.
- Pfizer and BioNTech filed an application to get their vaccine FDA-approved that would let them market the vaccine to people.
- Canada’s deal with Pfizer will get us up to 125 million booster doses by 2024 with the option to buy an extra 60 million doses in 2024.
Patent Pending: But while Pfizer had a great quarter, the threat of a suspension of intellectual property (IP) rights on the COVID-19 vaccine looms.
- Progressive activists are pressuring the government to remove intellectual property rights on the vaccine so less developed countries can produce it without Pfizer’s involvement.
- The move would significantly expand production, but industry experts warn it could set a terrible precedent for the pharma sector that relies on IP rights to justify high R&D costs.
Zoom out: Pfizer’s latest round of profits may add ammunition to the push to suspend intellectual property rights considering how much the company’s already made off the vaccine.